-
ALSO READ
Lincoln Pharma gets Indian patent for diclofenac rectal spray
Alembic Pharmaceuticals receives USFDA approval for ANDA Bromfenac Ophthalmic Solution 0.09%
Alembic Pharma gets USFDA nod for cholesterol lowering drug
Alembic Pharma JV gets USFDA nod for plaque psoriasis treatment drug
Alembic Pharma gets USFDA nod for seizure treatment drug
-
Alembic Pharmaceuticals announced that the company's joint venture, Aleor Dermaceuticals, has received US Food and Drug Administration (USFDA) Tentative Approval for Diclofenac Sodium Topical Solution USP, 2% w/w.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pennsaid Topical Solution, 2% w/w, of HZNP Medicines LLC (HZNP).
Diclofenac Sodium Topical Solution USP, 2% w/w is indicated for the treatment of the pain of osteoarthritis of the knee(s).
Diclofenac Sodium Topical Solution USP, 2% w/w, has an estimated market size of US$ 974 million for twelve months ending December 2018 according to IQVIA.
Diclofenac Sodium Topical Solution USP, 2% w/w, has an estimated market size of US$ 974 million for twelve months ending December 2018 according to IQVIA.
Alembic has a cumulative total of 109 ANDA approvals (96 final approvals and 13 tentative approvals) from USFDA.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
RECOMMENDED FOR YOU